Microbiota-Based Live Biotherapeutic Products for Clostridioides Difficile Infection- The Devil is in the Details
Lea Monday,Glenn Tillotson,Teena Chopra
DOI: https://doi.org/10.2147/idr.s419243
2024-02-16
Infection and Drug Resistance
Abstract:Lea Monday, 1 Glenn Tillotson, 2 Teena Chopra 1 1 Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USA; 2 GlennTillotson PhD, FIDSA, GSTMicro, Henrico, VA, USA Correspondence: Lea Monday, Harper University Hospital, Division of Infectious Diseases, 3990 John R Street, 5 Hudson, Suite 5911, Detroit, MI, 48201, USA, Tel +1 734-344-8392, Fax +1 313-9930302, Email Clostridioides difficile infection (CDI) remains a significant contributor to healthcare costs and morbidity due to high rates of recurrence. Currently, available antibiotic treatment strategies further disrupt the fecal microbiome and do not address the alterations in commensal flora (dysbiosis) that set the stage for CDI. Advances in microbiome-based research have resulted in the development of new agents, classified as live biotherapeutic products (LBPs), for preventing recurrent CDI (rCDI) by restoring eubiosis. Prior to the LBPs, fecal microbiota transplantation (FMT) was available for this purpose; however, lack of large-scale availability and safety concerns have remained barriers to its widespread use. The LBPs are an exciting development, but questions remain. Some are derived directly from human stool while other developmental products contain a defined microbial consortium manufactured ex vivo, and they may be composed of either living bacteria or their spores, making it difficult to compare members of this heterogenous drug class to one another. None have been studied head-to head or against FMT in preventing rCDI. As a class, they have considerable variability in their biologic composition, biopharmaceutic science, route of administration, stages of development, and clinical trial data. This review will start by explaining the role of dysbiosis in CDI, then give the details of the biopharmaceutical components for the LBPs which are approved or in development including how they differ from FMT and from one another. We then discuss the clinical trials of the LBPs currently approved for rCDI and end with the future clinical directions of LBPs beyond C. difficile . Keywords: Clostridioides difficile infection, microbiome, microbiome therapeutic, indirect treatment comparison The study of bacteria and their role in disease has been queried by humans for centuries. In the last two decades, advances in genomic sequencing technology have accelerated understanding of the gut microecosystem and led to a surge in microbiome-based research. 1–3 The quest to harness the power of the human microbiome into a commercially available product has resulted in a proverbial gold rush in drug development. Biotechnology startups have worked to discover novel microbiome-based drug candidates, and those with exceptional promise have been acquired by large pharmaceutical companies with the capital to bring them to commercial development. 4,5 In 2022 and 2023, the Food and Drug Administration (FDA) issued the first approvals of such agents for the prevention of recurrent Clostridioides difficile infection (rCDI) in the United States (US). 6 These drugs, derived from the human gut microbiome, have been designated a new class of medication called live biotherapeutic products (LBPs) or microbiome-based therapeutics (MBTs). Prior to these drugs, the only option for rCDI was fecal microbiota transplant (FMT). The FDA defines an LBP as a biological product that: 1) contains live organisms, such as bacteria; 2) is applicable to the prevention, treatment, or cure of a disease or condition of human beings; 3) is not a vaccine; and 4) as a general matter, is not administered by injection. 7 FDA approval of two LBPs represents a major milestone in the path from bench to bedside for drug development; however, significant questions remain about this drug class. The LBPs currently approved or under investigation are either derived directly from human stool or contain a defined microbial component isolated from human stool during development and then processed for manufacture ex vivo. 8–16 None of the LBPs have been studied either head-to head or against FMT in preventing rCDI. There is variability among the LBPs in their composition, biopharmaceutical science, dosage form design, and stages of development. 3,17 Lastly, the human clinical trials for these agents in preventing rCDI had heterogeneity in study design, patient population, and clinical endpoints which make their comparison difficult. In this review, we aim to clear up some of this confusion by discussing the LBPs and explaining how they differ not only from conventional FMT but from one another. First, we will explain the role of the gut microbiome in Clostridioides difficile infection (CDI) and the morbidity of its rec -Abstract Truncated-
pharmacology & pharmacy,infectious diseases